The Estimate of Interferon-inducible Protein-10 and Interferon-γ in Hemodialysis Patients with Chronic HCV


  • Mahmood Abdujabar Altobje Department of Biology, College of Science, University of Mosul, Mosul, Iraq
  • Zeyad Thanoon Al-Rrassam Department of Biophysics, College of Science, University of Mosul, Mosul, Iraq



Alkaline phosphatase, CXCL-10, HCV, Hemodialysis, Interferon


BACKGROUND: Due to the rise in the number of deaths, the hepatitis C virus remains a public health issue worldwide. During the recovery period, cytokines are known as indicators of chronic liver infection.

AIM: In this study, immunological parameters were measured and calculated in chronic hemodialysis patients after more than 6 months of drug administration.

METHODS: We have picked 60 patients with hemodialysis who are anti-HCV positive. ELISA and the calculation of alkaline phosphatase (ALP) were used to evaluate IP-10 and IFN-γ.

RESULTS: A substantial association between variables and infected cases was found. No worth was considered for genders or age categories.

CONCLUSIONS: The serum IP-10 level can be a warning primarily for patients who have taken a variety of prescriptions intermittently. In both the RPT and RST cohorts, IFN-γ serum levels are usually elevated. Serum level ALP is not a particular chronic HCV predictor.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Lu MY, Huang CI, Dai1CY, Wang SC, Hsieh MY, Hsieh MH, et al. Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Sci Rep. 2016;6:22995. PMid:26965318 DOI:

Etik D, Ocal S, Boyacioglu A. Hepatitis C infection in hemodialysis patients: A review. Hepatology. 2015;7(6):885-95. PMid:25937865

Vigani A, Pavan M, Tozzo R, Gonçales E, Lazarini M, Oliveira A, Gonçales F. Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C. Case Report. 2009;21:93-5. DOI:

Yu YC, Wang Y, He CL, Wang MR, Wang YM. Management of hepatitis C virus infection in hemodialysis patients. Hepatology. 2014;6(6):419-25. PMid:25018852 DOI:

Brownell J, Polyak S. Molecular pathways: Hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res. 2013;19(6):1347-52. PMid:23322900 DOI:

Tsuge M, Fujimoto Y, Hiraga N, Zhang Y, Ohnishi M, Kohno T, et al. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse. Plos One. 2011;6(8):e23856. PMid:21886832 DOI:

Barakat A, Hegazy A, Farag R, Abdul Baky A, Arafa L, Farouk A. Role of interferon-gamma and immune response biomarkers in predicting IFN-alpha responsiveness and treatment outcome in patients with Hepatitis C virus. Int J Virol. 2012;8(4):288-98. DOI:

Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Investigation. 2011;121(1):308-17. PMid:21183794 DOI:

Mascia C, Vita S, Zuccalà P, Marocco R, Tieghi T, Savinelli S, et al. Changes in inflammatory biomarkers in HCV infected patients undergoing direct-acting antiviral-containing regimens with or without interferon. PLoS One. 2011;3:1-14.

Miyaki E, Hiraga N, Imamura M, Uchida T, Kan H, Tsuge M, et al. Interferon-alpha treatment stimulates interferon-gamma expression in Type I NKT cells and enhances their antiviral effect against Hepatitis C virus. PLoS One. 2017;2:1-2. PMid:28253324

Caragea D, Mihaliovici A, Streba C, Schenker M, Ungureanu B, Caragea I, et al. Hepatitis C infection in hemodialysis patients. Curr Health Sci J. 2017;44(2):107-12. PMid:30746156 DOI:

Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM. Interferon (IFN)-gamma inducible protein-10: Association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic Hepatitis C virus infection. J Infect Dis. 2006;194(7):895-903. PMid:16960776 DOI:

Omran D, Hamdy S, Tawfik S, Esmat S, Saleh D, Zayed R. Association of Interferon-γ inducible protein-10 pretreatment level and sustained virological response in HCV-positive Egyptian patients. Ann Clin Lab Sci. 2014;44(2):167-72. PMid:24795055

Crisan D, Grigorescu M, Radu C, Suciu A, Grigorescu M. Interferon-γ-inducible protein-10 in chronic Hepatitis C: Correlations with insulin resistance, histological features and sustained virological response. Indian J Med Res. 2017;145(4):543-50. PMid:28862188

Huang Y, Chen X, Konduri M, Fomina N, Lu J, Jin L, et al. Mechanistic link between the anti-HCV effect of interferon gamma and control of viral replication by a Ras-MAPK signaling cascade. Hepatology. 2006;43(1):81-90. PMid:16374867 DOI:

Shin EC, Protzer U, Untergasser A, Feinstone S, Rice S, Hasselschwert D, et al. Liver-directed gamma interferon gene delivery in chronic Hepatitis C. J Virol. 2005;79(21):13412-20. PMid:16227262 DOI:

Khedmat H, Amini M, Ghamar-Chehreh M, Agah S. Hepatitis C virus infection in dialysis patients. Saudi J Kidney Dis Transpl. 2014;25(1):1-8. PMid:24434375 DOI:

Agarwal S, Bagchi S, Yadav R. Hemodialysis patients treated for Hepatitis C using a sofosbuvir-based regimen. Kidney Int Rep. 2017;2(5):831-5. PMid:29270489 DOI:

Dawood A, Khaleel A, Hayawi A. Estimate viral RNA of hepatitis C of β-thalassemia patients in Nineveh province. EJMCM. 2020;7(10):1-8.

Dawood A, Altobje M, Al-Rrassam Z. Adoption of Euvax-B vaccine in Nineveh. VacciMonitor. 2021;30(2):91-5.




How to Cite

Altobje MA, Al-Rrassam ZT. The Estimate of Interferon-inducible Protein-10 and Interferon-γ in Hemodialysis Patients with Chronic HCV. Open Access Maced J Med Sci [Internet]. 2021 Oct. 9 [cited 2024 Apr. 12];9(A):928-33. Available from: